Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration.
There has been growing interest in the use of retinal imaging for tracking disease progression in multiple sclerosis. However, systematic and detailed pathological descriptions of retinal tissue in multiple sclerosis are lacking. Graded, histological evaluations on eyes from 82 patients with multiple sclerosis and 10 subjects with other neurological diseases, with immunohistochemistry on a subset, were performed and correlated with clinical and pathological findings. Multiple sclerosis cases demonstrated evidence of retinal atrophy and inflammation even in late-stage disease. Retinal ganglion cell loss was significant and remaining neurons appeared shrunken and were partially engulfed by human leukocyte antigen-DR positive cells with the phenotype of microglia in samples subjected to immunohistochemistry. Neurofilament staining revealed variable but prominent degrees of axonal loss and injury. Neuronal loss was noted in the inner nuclear layer with focal reduction in cell density. Foamy-appearing human leukocyte antigen-DR positive cells were evident near vessels and periphlebitis was found in a small but significant number of multiple sclerosis cases. Glial fibrillary acidic protein staining showed extensive astrocyte hypertrophy and proliferation with prominent gliosis in multiple sclerosis cases. Frequent but previously unreported abnormalities in the iris were documented in the majority of chronic multiple sclerosis cases. The injury to both iris and retina could be seen at all stages of disease. Severity of retinal atrophy was correlated with overall brain weight at time of autopsy (P = 0.04) and a trend for increased atrophy was seen with longer disease duration (P = 0.13). This study provides the first large-scale pathological description of retinas in multiple sclerosis, including patients with different subtypes of disease at all stages, and with variable clinical severity. Changes were seen not only in the retinal nerve fibre layer and ganglion cell layer, but also in the inner nuclear layer, suggesting that retinal injury is more widespread than previously appreciated. Furthermore, the human retina is devoid of myelin, but inflammation was demonstrated to be prominent in multiple sclerosis and to persist in the retina at late stages of disease. The prominent gliosis and inflammation surrounding vessels of the inner retina could potentially impact optical coherence tomography evaluations in multiple sclerosis-as standard techniques exploit presumed differences in tissue reflectivity and utilize automated edge detection algorithms to judge axon loss in the nerve fibre layer. Deciphering the relationships between the different types of retinal pathology may aid us in understanding the factors that drive both inflammation and tissue atrophy in multiple sclerosis.
Green
Ari J
AJ
Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA. agreen@ucsf.edu
McQuaid
Stephen
S
Hauser
Stephen L
SL
Allen
Ingrid V
IV
Lyness
Roy
R
D000208:Acute Disease; D000328:Adult; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000378:metabolism / Q000473:pathology*; D020528:Multiple Sclerosis, Chronic Progressive / Q000378:metabolism / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000378:metabolism / Q000473:pathology; D009422:Nervous System Diseases / Q000378:metabolism / Q000473:pathology; D012160:Retina / Q000378:metabolism / Q000473:pathology*; D012162:Retinal Degeneration / Q000378:metabolism / Q000473:pathology*; D012173:Retinitis / Q000378:metabolism / Q000473:pathology*; D013997:Time Factors
Ann Neurol. 1999 Nov;46(5):747-54
10553992
N Engl J Med. 2006 Mar 23;354(12):1273-80
16554529
AMA Arch Ophthalmol. 1953 Dec;50(6):718-26
13103872
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2520-7
10509645
Eye (Lond). 1987;1 ( Pt 4):441-65
3327709
Ocul Immunol Inflamm. 2000 Sep;8(3):149-57
11120576
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1439-45
19892867
Br J Ophthalmol. 2002 Sep;86(9):978-80
12185119
Neurology. 2007 May 1;68(18):1488-94
17470751
Am J Ophthalmol. 2005 Jun;139(6):1101-8
15953446
Ann Neurol. 1983 Mar;13(3):227-31
6847134
Brain. 2009 Mar;132(Pt 3):628-34
19224900
Retina. 1994;14(5):445-51
7899721
Ophthalmology. 2004 Mar;111(3):513-7
15019328
Curr Opin Ophthalmol. 2007 Mar;18(2):110-4
17301611
Brain Pathol. 2004 Apr;14(2):148-57
15193027
J Neurol Sci. 2001 Jun 15;187(1-2):49-53
11440744
Brain. 1991 Dec;114 ( Pt 6):2437-50
1782525
Ann Neurol. 2005 Sep;58(3):383-91
16075460
Mayo Clin Proc. 1972 May;47(5):335-40
4555346
Acta Neurol Scand Suppl. 1965;15:1-161
5213727
Mult Scler. 2008 Apr;14(3):415-7
18208897
J Neuroimaging. 2007 Apr;17 Suppl 1:10S-15S
17425728
Acta Ophthalmol (Copenh). 1990 Apr;68(2):218-20
2356712
J Neurol Sci. 1987 Feb;77(2-3):147-52
3819765
Exp Eye Res. 2008 Sep;87(3):208-13
18653182
Arch Ophthalmol. 1974 Aug;92(2):91-7
4847508
Brain. 2007 May;130(Pt 5):1244-53
17472983
Neurol Res. 1996 Jun;18(3):233-6
8837058
Doc Ophthalmol. 2006 Sep;113(2):123-32
16972082
Brain. 2008 Jan;131(Pt 1):277-87
18056739
J Clin Neuroophthalmol. 1983 Sep;3(3):211-20
6226722
Neurology. 1999 Jan 1;52(1):179-81
9921871
Arch Neurol. 2008 Jun;65(6):727-32
18541792
Eye (Lond). 2009 Jan;23(1):171-5
17721504
Ann Neurol. 1997 Nov;42(5):783-93
9392578
Brain. 2005 Nov;128(Pt 11):2705-12
16230320
J Neurol Neurosurg Psychiatry. 1989 Dec;52(12):1360-3
2614430
Am J Ophthalmol. 1954 Apr;37(4):487-94
13148276
Brain. 2001 Sep;124(Pt 9):1813-20
11522583
Arch Ophthalmol. 1996 Jan;114(1):34-9
8540848
Can J Neurol Sci. 1982 Aug;9(3):325-30
7116240
Ophthalmology. 2006 Feb;113(2):324-32
16406539
Nat Med. 2009 Jun;15(6):626-32
19483694
Invest Ophthalmol Vis Sci. 2008 May;49(5):1940-5
18436826
Ophthalmology. 1984 Mar;91(3):255-62
6717913
Ann Neurol. 2006 Jun;59(6):963-9
16718705
J Neuropathol Exp Neurol. 2008 Mar;67(3):200-11
18344911